HKBU Foundation Annual Report 2020-21

20 A team led by Dr. Ren Kangning, Associate Professor of the Department of Chemistry, developed a novel cell sensor that enables rapid and low-cost screening of drug-resistant bacteria. The invention could potentially be used on a large scale in resource-limited situations such as frequent safety screenings of water, food and public facilities, as well as urgent surveys of massive samples during an infectious disease outbreak. 化學系副教授任康寧博士的團隊研發出創新的細胞傳感 器，能以低成本為耐 性細菌作快速篩查，可望在資源有 限的條件下被大規模應用，如為食水、食物和公用設施進 行頻密的測試，以及在傳染病爆發期間緊急為大量樣本進 行檢測。 A project led by Professor Guo Yike, Vice-President (Research and Development), and Professor Johnny M Poon, Associate Vice-President (Interdisciplinary Research) and Dr. Hung Hiu Shiu Endowed Professor in Music, was awarded HK$52.83 million in research funding by the Research Grants Council (RGC) for a five-year project entitled “Building Platform Technologies for Symbiotic Creativity in Hong Kong”. This is the first major funding to be allocated by the RGC for an art-tech project. 副校長（研究及拓展）郭毅可教授和協理副校長（跨學 科研究）潘明倫教授兼孔憲紹博士音樂教授領導的研究  計劃「香港人機共生藝術創造平台技術建設」，獲研究資助 局撥款港幣 5,283 萬元，進行為期五年的研究，是該局首次 對藝術創意技術項目撥出大筆資助。 HKBU has established the Centre for Chinese Herbal Medicine Drug Development (CDD), which is equipped with comprehensive and cutting-edge facilities that can enhance Hong Kong's ability to develop novel Chinese medicine (CM) drugs. It will also standardise and internationalise the development of CM drugs, and nurture talent for the industry. The CDD was established with funding from the InnoHK initiative under the Innovation and Technology Commission of the HKSAR Government. The Centre’s vision is to translate traditional CM wisdom into pharmaceutical products with the best global partners using international standards. 浸大成立「中 創新研發中心」，配備完善和先進的設施， 提升本港開發創新中 的能力，引領中 開發走向標準化 和國際化，並為業界培養人才。這個一站式中 研發平 台，獲特區政府創新科技署的「 InnoHK 創新香港研發平 台」資助成立。中心將匯集世界級合作夥伴，共同將傳統 中醫 智慧轉化為醫 產品。 In collaboration with Cornell University, Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development), and his team developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid, which could be a more effective therapeutic option for TNBC. The study was supported by the Vincent and Lily Woo Foundation and was published in Frontiers in Oncology . 協理副校長（中醫 發展）卞兆祥教授及團隊與康奈爾大 學合作，設計以納米載體運送中 成份藤黃酸，研發出治 療三陰性乳癌的全新標靶療法，療效有望大為提升。該研 究獲吳文政王月娥基金會資助，其成果已刊登於醫學期刊  Frontiers in Oncology 。 Innovative Research 創新研究